Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.
Dr. Robert French is a Senior Research Fellow at Cardiff University's School of Social Sciences. His work focuses on the intersection of health, education, and social policy, with a particular emphasis on data linkage methodologies to address disparities in healthcare and educational outcomes. He leads projects such as the ADR UK-funded initiative to establish frameworks for linking child health and education datasets in England and Wales. Key research interests include educational attainment dynamics, health inequalities among LGBTQ+ populations, and the impact of chronic conditions like diabetes on academic performance. His recent work explores factors influencing Special Educational Needs identification in Wales and the long-term outcomes of Graves' disease therapies. French's publications span epidemiology, public health, and social sciences, with methodological expertise in multilevel modeling and data integration. He collaborates with institutions like NHS Digital, the Royal College of Paediatrics and Child Health, and universities across Europe to advance evidence-based policymaking. His current projects include analyzing prescribing costs for diabetes treatments in Wales and examining cardiovascular risks linked to Graves' disease. French is also involved in public engagement, including workshops with Diabetes UK to inform ethical data usage frameworks. He holds leadership roles in multidisciplinary research teams and has secured grants from ADR UK and Wellcome Trust. His office is located at the University Hospital of Wales, Cardiff, reflecting his clinical and academic collaborations.
Prof. Dr. Harald Tauchmann is a Professor of Health Economics at Friedrich-Alexander University Erlangen-Nuremberg (FAU), where he has held a faculty position since 2013. He is affiliated with the School of Business, Economics and Social Sciences, specifically within the Department of Economics. Prof. Tauchmann also participates in multiple research focus areas at FAU, including 'Insurance and Risk' and 'Work in Transition,' demonstrating his interdisciplinary approach to health economics. Prof. Tauchmann received his education at Heidelberg University and the University of Manchester, UK, where he studied economics, political science, and sociology. He graduated in 1998 and completed his doctorate at the Interdisciplinary Institute for Environmental Economics (University of Heidelberg) in 2003. Prior to joining FAU, he worked as a research associate at the Rhineland-Westphalian Institute for Economic Research (RWI) in Essen from 2003 to 2012 and headed a junior research group at the health economics research center CINCH at the University of Duisburg-Essen. His research expertise lies in empirical health economics, with a particular emphasis on health insurance choice and competition, as well as individual health behavior. He has made significant contributions to understanding obesity, health shocks, mental health care payment systems, and thyroid diagnostics through his extensive publication record. His methodological work includes developing specialized Stata modules for econometric analysis, which have been widely adopted by researchers in the field. Prof. Tauchmann's scholarly work demonstrates a consistent focus on applying rigorous econometric methods to pressing health policy questions. His research portfolio shows particular strength in causal analysis of health behavior, especially regarding obesity interventions, health insurance market dynamics, and the economic consequences of health shocks. His recent publications (including several forthcoming in 2025) indicate continued scholarly productivity and relevance to current health policy debates. From March 2021 to April 2022, Prof. Tauchmann served as chairman of the German Society for Health Economics, highlighting his leadership and recognition within the national health economics community. His email contact is harald.tauchmann@fau.de for professional inquiries.
Brian M. Barnes is a Professor of Zoophysiology at the University of Alaska Fairbanks (UAF), affiliated with the Institute of Arctic Biology and the Department of Biology and Wildlife. He has held roles including INBRE Director, Toolik Field Station Co-PI, and Interim Director of the Institute of Arctic Biology. His research focuses on physiological ecology, endocrinology of hibernation, and biological rhythms in Arctic animals. Education: BS in Biology (UC Riverside, 1977); PhD in Zoology (University of Washington, 1983). Postdoctoral training at UC Berkeley and international collaborations in Norway and the Netherlands. Awards include NSF grants and leadership in Arctic research networks. Research Interests: Hibernation physiology and mechanisms Circadian rhythms in polar vertebrates Overwintering strategies of Arctic mammals and insects Climate change impacts on animal phenology Notable Contributions: Discovered freeze-avoidance mechanisms in Arctic ground squirrels Pioneered studies on hibernation energy conservation and metabolic suppression Co-developed tools for field studies at the Toolik Field Station Lab/Teams: Leads research groups studying Arctic hibernators, including collaborations on black bear hibernation genomics and insect antifreeze proteins. Advises students in physiology, ecology, and comparative biology.
Helen Suh is a Professor at Tufts University, jointly appointed in the departments of Civil and Environmental Engineering and Community Health . As an internationally-recognized expert in air pollution health effects, she combines environmental epidemiology , exposure science , and data analytics to investigate how pollutants impact human health. Sc.D. , Harvard University (1993) M.S. , Harvard University (1990) S.B. , Massachusetts Institute of Technology (1985) Her research focuses on three areas: air pollutant impacts on cognitive performance and child development , multi-pollutant health effects , and GIS-based spatio-temporal modeling for epidemiological studies. Recent publications highlight her work on PM2.5 measurement error correction , hormonal disruptions in pregnancy , and machine learning applications in environmental health analysis. Current trends include: Advanced statistical methods for exposure assessment Multi-omics approaches to cardiometabolic health International comparative studies (e.g., Tehran, Puerto Rico) Long-term mortality analysis in Medicare populations Pollution-immune system interactions in vulnerable groups Policy-relevant modeling for air quality standards Helen Suh has served as an Associate Editor for the Journal of Exposure Science and Environmental Epidemiology and advised major U.S. and international health organizations. Her work spans over 150 publications and integrates multidisciplinary team leadership in environmental health science. Her laboratory develops large-scale data analytics tools and spatio-temporal exposure models to support population-level health research. Current projects include air pollution and aging cohorts , urban environmental noise measurement , and epigenetic responses to pollutants .
Professor Susan Brooks is a faculty member at Oxford Brookes University in the School of Biological and Medical Sciences . Her research focuses on glycobiology , cancer progression , and the role of extracellular vesicles in metastasis. Professor of Cell Biology Director of Researcher Development Focus on breast and ovarian cancer Specialized in glycosylation mechanisms Research Interests : Dr. Brooks' work explores how aberrant glycosylation of proteins and glycans influences cancer cell behavior, including metastasis and drug resistance . Her recent studies examine extracellular vesicles as diagnostic tools and therapeutic targets. Article Trends : Over 25 years, Dr. Brooks has published 15+ articles on glycosylation patterns in breast and ovarian cancer. Key areas include lectin binding , miRNA regulation , and radiation-induced metastatic changes . Her work bridges cell biology and clinical applications .
James Lacefield is a Professor in both the Department of Electrical and Computer Engineering and the Department of Medical Biophysics at Western University. He serves as Director of the School of Biomedical Engineering and maintains his research laboratory in the Amit Chakma Engineering Building. His academic appointments span multiple disciplines, reflecting the interdisciplinary nature of his work in biomedical ultrasound imaging. Dr. Lacefield earned his Ph.D. and B.S.E. in Biomedical Engineering from Duke University. His educational background established the foundation for his current research program that bridges engineering principles with medical applications. His research focuses on the physical acoustics and signal processing aspects of ultrasound imaging, with particular emphasis on quantitative vascular imaging applications. Dr. Lacefield's laboratory develops novel methods for color Doppler, power Doppler, and contrast-enhanced ultrasound imaging, with primary applications in cancer research. Current projects include optimization of high-resolution ultrasound systems for tumor vascular characterization and development of methods to quantify spatial blood flow distribution in tumors. Analysis of his recent publications reveals a strong focus on quantitative ultrasound techniques for cancer applications, with particular attention to tumor perfusion assessment using contrast-enhanced ultrasound. His work demonstrates increasing sophistication in speckle analysis methods to improve the reliability of perfusion measurements in preclinical tumor models. Associate Editor, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control Member, Council of Chairs of Bioengineering and Biomedical Engineering Member, College of Reviewers, Canadian Institutes of Health Research Dr. Lacefield maintains active collaborations with multiple research groups including the Imaging Research Laboratories at Robarts Research Institute. His professional activities include editorial work for major ultrasound journals and participation in national review panels for biomedical research funding.
Professor Andreas Kortenkamp is a leading academic in the field of Human Molecular Toxicology, affiliated with Brunel University's Department of Life Sciences within the College of Health, Medicine and Life Sciences. His research focuses on understanding combined effects of environmental pollutants, developing regulatory strategies for chemical mixtures, and studying hormonal carcinogenesis. Education and Career: Bachelor's in Chemistry, Philosophy, and Educational Sciences (University of Münster, 1983) PhD in Chemistry (University of Bremen, 1989) Post-doctoral Fellowships and academic roles at Queen Mary University of London and the School of Pharmacy, University of London (1990–2011) Since 2011, Professor at Brunel University's Institute for the Environment Research Interests: Mixture toxicology and predicting combined chemical effects Endocrine disruptors and their regulatory implications Hormonal mechanisms in breast cancer Impact of environmental chemicals on human and wildlife health Grants and Collaborations: EU-funded projects on endocrine disruptors and mixture toxicity Collaborations with institutions like the European Commission, WHO, and US National Academy of Sciences Contributions to policy decisions on chemical regulation Current Projects: State of the Art Assessment for Endocrine Disrupters (EU Commission) Research on semen quality decline linked to chemical mixtures Development of thyroid hormone disruption assays (ATHENA Project) Advising and Teams: Supervises PhD students in hormonal carcinogenesis and toxicology Leads research groups focused on environmental health and toxicology
Rabih Geha, MD is an Associate Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine. Based at the San Francisco VA Medical Center, he serves as the Director of Education for the Emergency Department, overseeing the education of Psychiatry, Emergency Medicine, and Internal Medicine residents. Clinically, Dr. Geha splits his time between the emergency room and the inpatient teaching wards, bringing practical experience to his educational roles. Dr. Geha completed his medical education at Alpert Medical School of Brown University in Providence, RI (MD, 2014), followed by residency training at UCSF (2017) and a chief residency at UCSF (2018). His educational background has provided a strong foundation for his current roles in medical education and clinical practice. Dr. Geha's research and professional interests center on clinical reasoning, diagnosis, medical education, and diagnostic schema development. He is particularly focused on innovative approaches to teaching diagnostic reasoning and improving medical decision-making processes. His work addresses critical challenges in medical education, including developing tolerance for ambiguity among medical students, addressing cognitive biases in clinical reasoning, and creating effective frameworks for diagnostic problem-solving. Dr. Geha is passionate about anti-racism initiatives in medicine and promoting women in medicine through his educational platforms. Analysis of Dr. Geha's publication record reveals a consistent focus on clinical reasoning education and diagnostic challenges. His work spans various medical specialties including internal medicine, hospital medicine, dermatology, endocrinology, and infectious diseases, demonstrating his broad clinical expertise. A notable trend in his research is the development of innovative educational tools and frameworks for clinical reasoning, including the exploration of natural language processing applications for case library development. His publications frequently address cognitive aspects of medical decision-making, diagnostic errors, and strategies for improving diagnostic accuracy. Dr. Geha is the co-founder of Clinical Problem Solvers, a multimodal medical education venture run by a global and diverse team. This initiative hosts a weekly podcast covering topics such as diagnostic reasoning, anti-racism, and women in medicine, along with virtual morning reports and a clinical reasoning training academy. Through this platform, he has significantly impacted medical education beyond the UCSF campus, reaching a worldwide audience of medical learners and educators.
Sylvie Dufour is an Associate Research Scientist in the Department of Endocrinology at Yale School of Medicine, part of Yale University. Her research focuses on metabolic disorders, mitochondrial dysfunction, and insulin resistance, with a particular emphasis on liver and muscle metabolism in diabetes and fatty liver disease. She collaborates closely with prominent researchers like Gerald I. Shulman and Kitt Petersen. Key research themes include the role of glucagon in hepatic mitochondrial oxidation, the impact of genetic variants (e.g., PNPLA3 I148M) on lipid metabolism, and interventions like carbohydrate restriction or SGLT2 inhibitors to reverse metabolic dysfunction. Her work bridges basic science and clinical translation, addressing mechanisms underlying insulin resistance, hepatic steatosis, and cardiometabolic risk. Publications span topics such as mitochondrial protonophore therapies, ketogenesis modulation, and the effects of burosumab on muscle function. Her studies frequently employ human and animal models to elucidate metabolic pathways and therapeutic targets.
Julia F. Slejko, PhD, is an Associate Professor in the Department of Practice, Sciences, and Health Outcomes Research (P-SHOR) at the University of Maryland School of Pharmacy. She serves as Co-Director of the Patient-Driven Values in Healthcare Evaluation (PAVE) Center and Director of the Pharmaceutical Health Services Research Graduate Program. Dr. Slejko is actively involved in ISPOR, where she co-leads the Women in HEOR initiative and serves on the Faculty Advisor Council and Health Science Policy Council. BA in Molecular, Cellular and Developmental Biology – University of Colorado Boulder PhD in Pharmacoeconomics – University of Colorado School of Pharmacy, Center for Pharmaceutical Outcomes Research Postdoctoral Training – Pharmaceutical Outcomes Research and Policy Program, University of Washington School of Pharmacy Dr. Slejko’s research centers on health economic modeling and patient-informed value assessment. She investigates how real-world evidence, particularly medication adherence, influences cost-effectiveness analyses and healthcare decision-making. Her work integrates patient preferences into value frameworks, especially for chronic conditions like COPD, mental health disorders, and cancer. She also explores disparities in treatment outcomes related to socioeconomic and geographic factors. Her recent publications (2020–2023) demonstrate a strong focus on patient-centered outcomes, microsimulation modeling, and economic burden analyses across oncology, psychiatry, and respiratory diseases. Themes include stakeholder engagement, treatment preferences, and the economic impact of comorbidities and health inequities. Dr. Slejko mentors students through her role as faculty advisor for the UMB ISPOR Student Chapter and teaches graduate courses in research methods and pharmacoeconomics. She leads interdisciplinary research teams within the PAVE Center, fostering collaboration between patients, clinicians, and policymakers. She has no listed scientific awards in the provided text, though her leadership roles suggest professional recognition. She advises on student research and is involved in grant-funded projects related to patient-driven value assessment, though specific grants are not detailed.
Julie K. Schwarz, MD, PhD, FASTRO is a tenured Professor of Radiation Oncology at Washington University School of Medicine, where she serves as Vice-Chair of Research and Director of the Cancer Biology Division. She also holds appointments as Professor of Cell Biology and Physiology and is affiliated with the Roy and Diana Vagelos Division of Biology & Biomedical Sciences, specifically within the Cancer Biology and Molecular Cell Biology programs. Dr. Schwarz is a key member of the Siteman Cancer Center and co-leads one of only five centers comprising the NIH's Radiation Oncology-Biology Integration Network (ROBIN). Dr. Schwarz completed her BS in Biology at Duke University (1995) followed by an MD/PhD in Cell and Molecular Biology at Washington University School of Medicine (2004) through the Medical Scientist Training Program. She completed her Internal Medicine internship (2005) and Radiation Oncology residency (2009) at Barnes-Jewish Hospital, becoming board-certified by the American Board of Radiology in Radiation Oncology (2010). Her research program focuses on translational studies of gynecologic cancers, particularly cervical cancer, with emphasis on tumor metabolism, biomarker discovery, and treatment resistance mechanisms. Dr. Schwarz's laboratory maintains one of the largest tumor repositories for cervical cancer, which includes specimens collected before and during chemoradiation treatment. Her work has demonstrated the critical role of pretreatment and post-treatment FDG-PET scanning for cervical cancer patients and has identified alterations in PI3K/Akt pathway genes associated with treatment response. Recent research directions include studying obesity's paradoxical favorable impact on cervical cancer outcomes, glucose and glutamine metabolism as targets for cancer therapy, and the role of tumor immunology in therapy resistance. Analysis of Dr. Schwarz's most recent publications reveals a strong focus on cervical cancer biology, tumor metabolism, and novel therapeutic approaches. Her work integrates clinical data with laboratory research to identify biomarkers and develop improved treatment strategies. Current research emphasizes the interface between tumor metabolism, the microenvironment, and response to therapy, with particular attention to HPV-related cancers, tumor imaging, and metabolic targets for radiosensitization. Fellow of American Society for Radiation Oncology (ASTRO) (2024) Danforth WashU Physician-Scientist Scholar Award (2024) Elected into American Society for Clinical Investigation (2022) Michael Fry Research Award for Outstanding Junior Investigator: Radiation Research Society (2012) Fellow: National Cancer Care Network (2008) RSNA Roentgen Resident/Fellow Research Award (2008) As a dedicated mentor, Dr. Schwarz has guided numerous trainees across all levels including undergraduates, graduate students, medical students, residents, fellows, and postdoctoral researchers. Her Schwarz Lab is highly collaborative and actively recruits students and researchers, with recent successes including Leahan Castillo receiving an Honorable Mention at AACR and Brett Tortelli developing significant research on the vaginal microbiome's relationship to cervical cancer treatment response. Dr. Schwarz is R01-funded and leads multiple research projects, including work on the TARGET Center which focuses on understanding the biologic effects of radiation therapy in cancer treatment. She actively participates in national organizations including the ASTRO/NCI Radiobiology Consensus Workshop, AACR Radiation Oncology Think Tank, and the ASTRO Community of Radiation Oncology Physician Scientists. Dr. Schwarz directs the Schwarz Lab, which is growing and actively recruiting postdocs, staff scientists, and graduate students. The lab employs a multidisciplinary approach combining well-annotated clinical databases, prospectively collected patient tumor banks, and state-of-the-art sequencing technologies. Current research directions include single-cell sequencing approaches to study treatment effects on tumor cells and immune cells within the tumor microenvironment, glucose and glutamine metabolism as targets for cancer therapy, and targeting myeloid-derived cells to improve anti-tumor immunity. The lab is highly collaborative and studies multiple tumor types including cervical, pancreatic, and ovarian cancers.
Scott T. Doyle is an Associate Professor in the Department of Pathology and Anatomical Sciences at the Jacobs School of Medicine & Biomedical Sciences, University at Buffalo. His research integrates biomedical imaging, artificial intelligence, and computational pathology to develop quantitative tools for clinical diagnostics and anatomical modeling. Education: PhD in Biomedical Engineering, Rutgers, The State University of New Jersey (2011) BS in Biomedical Engineering, Rutgers, The State University of New Jersey (2006) Optical Microscopy & Imaging in the Biomedical Sciences, Marine Biological Laboratory (2014) hES Stem Cell Culture Training, WNYSTEM (2014) R Bioconductor Training, Roswell Park Cancer Institute (2016) Dr. Doyle’s research focuses on developing AI-driven algorithms for biomedical image analysis, particularly in digital pathology and 3D anatomical modeling. His work spans tumor segmentation, risk prediction in oral and thyroid cancers, and integration of virtual and physical anatomy in medical education. He applies machine learning, deep learning, and computational modeling to enhance diagnostic accuracy and patient outcomes. His recent publications reflect a strong trend in applying artificial intelligence to histopathology, with emphasis on active learning, 3D reconstruction, and multi-institutional data fusion. Key areas include oral cavity cancer recurrence prediction, thyroid cancer subtyping, and computational modeling of surgical margins and anatomical structures. Scientific Service and Recognition: Reviewer for NIH SPORE grants Peer reviewer for journals including Medical Image Analysis , BMC Bioinformatics , IEEE Transactions on Biomedical Engineering Program Committee and Session Chair, SPIE Medical Imaging: Digital Pathology (2016–present) Member, Graduate Program Steering Committee, Pathology & Anatomical Sciences Mentor, McNair Scholarship and CSTEP programs for underrepresented students Dr. Doyle has secured significant research funding as Principal Investigator on NIH and CTSI grants, including a $2M+ NIH grant for predicting oral cancer recurrence. He has also contributed to educational innovation through hybrid anatomy curriculum development and AI training for pathologists. He leads the 'Atoms to Anatomy' research initiative and is active in strategic planning at the Jacobs School. Laboratories and Collaborative Teams: Dr. Doyle collaborates with the Center for Computational Research (CCR) and is involved in the Structural Sciences Learning Center (SSLC). He has led projects with teams at Ibris, Inc., Veterans Affairs Hospital, and Mount Sinai School of Medicine.
Dr. Yuan Lu serves as Assistant Professor of Medicine (Cardiology) and of Biomedical Informatics and Data Science and of Epidemiology (Chronic Diseases) at Yale School of Medicine. She is affiliated with multiple departments including Cardiovascular Medicine (primary appointment), Biomedical Informatics & Data Science, and Chronic Disease Epidemiology. Dr. Lu is also a key member of the Yale Center for Outcomes Research and Evaluation (CORE), where she collaborates with renowned researchers including Dr. Harlan Krumholz. Dr. Lu earned her ScD and MSc degrees in Global Health and Population from Harvard School of Public Health. Her educational background in epidemiology and global health has shaped her research trajectory at the intersection of cardiovascular disease prevention, clinical informatics, and digital health. Dr. Lu's research focuses on cardiovascular diseases prevention through implementation science, with particular emphasis on hypertension management, digital health interventions, and health equity. Her work leverages electronic health records from large healthcare systems to identify patients with persistent hypertension and design decision support systems to improve care. She has successfully completed an NHLBI K12 career development award in implementation science and currently serves as Principal Investigator for an NIH R01 grant leveraging real-world data from five electronic health record databases encompassing over 100 million US adults. Dr. Lu's publication portfolio demonstrates a strong focus on cardiovascular outcomes research, health disparities, and innovative treatment approaches. Her work spans clinical trials, epidemiological studies, and implementation science projects, with particular attention to racial and ethnic disparities in cardiovascular care. She has authored over 150 peer-reviewed publications in leading journals including The Lancet, JAMA, BMJ, Circulation, and JACC, with her work cited more than 50,000 times. Dr. Lu has received numerous honors including the 2022 John H. Laragh Research Award from the American Journal of Hypertension, and is a Fellow of both the American Heart Association and the American College of Cardiology. She currently serves as an Executive Associate Editor at JACC and has been recognized by Yale's Office of Health Equity Research for her contributions to health equity research. As a mentor, Dr. Lu advises multiple postdoctoral fellows, graduate students, and medical students. She has successfully completed an NHLBI K12 career development award and currently leads an NIH R01 grant focused on generating real-world evidence for hypertension treatment. Her collaborative work extends internationally, including groundbreaking projects between Yale University and the Chinese National Center for Cardiovascular Diseases in Beijing, such as the Millions Persons Project that assembles population health resources from 5 million individuals across China. Dr. Lu is actively involved with the Yale/YNHH Center for Outcomes Research and Evaluation (CORE), contributing to its mission of improving quality, transparency, and equity in healthcare. Her work exemplifies CORE's commitment to applying human-centered design, methodological rigor, and clinical insight to address pressing healthcare challenges.
Alex Banks is an Assistant Professor at Harvard Medical School and Beth Israel Deaconess Medical Center (BIDMC), with a focus on metabolic disorders. As Director of the Energy Balance core facility at BIDMC, he employs indirect calorimetry to study energy expenditure, food intake, and thermogenesis in mice. His research bridges genetic, pharmacological, and environmental factors to enhance understanding of obesity and metabolic diseases, while developing open-source tools like CalR to standardize metabolic analysis for the broader scientific community. Role: Assistant Professor Affiliation: Harvard Medical School, BIDMC Facility: Energy Balance Core Director Research Interests: The Banks Lab investigates mechanisms of obesity and metabolic disorders, emphasizing energy balance regulation through: Indirect calorimetry and metabolic rate analysis Genetic and pharmacological modulation of PPARγ Gut microbiome interactions with host metabolism Neural circuits controlling thermogenesis and food-seeking behavior Development of computational tools (CalR) for metabolic data Scientific Trends: Recent work spans obesity-linked phosphorylation of PPARγ, thermogenesis regulation via thyroid hormone, microbiome-dependent metabolic control, and novel methods for calorimetry. Collaborative projects address translational applications in bariatric surgery and metabolic drug development. Collaborations: The lab serves as a hub for Harvard/Boston-area researchers and provides freely accessible analytical tools to maximize utility of animal and human studies in combating obesity.
